Company intelligence / Profile preview
Expert Systems
Rockville, Maryland, United Statesexpertsystems.inc ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Expert Systems has demonstrated promising Phase 1 results with its next-generation BCL2 inhibitor, lonitoclax, showing improved safety and pharmacology over existing therapies like venetoclax. The company’s AI-enabled platform accelerates drug discovery from target identification through candidate selection, supporting rapid transition from in silico design to first-in-human trials. It has managed over 30 R&D programs globally.
- Therapeutic areas
- Oncology
- Modalities
- Small moleculesBCL2 inhibitors
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Lomond TherapeuticsRambam AGNLC Health VenturesEilean Therapeutics LLC
Beyond the preview
Go deeper on Expert Systems.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Expert Systems.